Who owns Decoy Therapeutics Inc.? Owners, funding and legal record

Before you sign or pay

• Court and bankruptcy: No federal court case or bankruptcy filing found under Salarius Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
• Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital, LLC (filed 2026-08-14).

Who is behind it

Decoy Therapeutics Inc.: incorporated in Delaware; business address in Houston, Texas; industry Pharmaceutical Preparations (S-1, 2026-10-07).

Officers and directors, each with the role and the filing that names them:

• Mark J. Rosenblum: Executive Officer (Form D, 2024-12-27)
• David J. Arthur: Director, Executive Officer (Form D, 2024-12-27)
• William McVicar: Director (Form D, 2024-12-27)
• Jonathan Lieber: Director (Form D, 2024-12-27)
• Tess Burleson: Director (Form D, 2024-12-27)
• Arnold C. Hanish: Director (Form D, 2024-12-27)
• Paul Lammers: Director (Form D, 2024-12-27)
• Bruce J. McCreedy: Director (Form D, 2024-12-27)

Money raised

Latest IPO step: Decoy Therapeutics Inc. filed to go public (S-1, 2026-10-07).

IPO filings: S-1, 2026-10-07, S-1, 2026-07-10, S-1, 2026-06-15, RW, 2026-06-05, 424B4, 2025-11-12; ticker DCOY on Nasdaq Capital Market.

Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2025-11-13).

Related pages

5%+ holders

Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.

All companies

Not for employment, credit, insurance or tenancy decisions.